Graypoint LLC Acquires 3,911 Shares of Pfizer Inc. (NYSE:PFE)

Graypoint LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 10.7% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 40,528 shares of the biopharmaceutical company’s stock after acquiring an additional 3,911 shares during the quarter. Graypoint LLC’s holdings in Pfizer were worth $1,075,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Atlas Brown Inc. increased its stake in Pfizer by 3.8% in the 4th quarter. Atlas Brown Inc. now owns 72,917 shares of the biopharmaceutical company’s stock worth $1,934,000 after acquiring an additional 2,701 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Pfizer by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 114,499 shares of the biopharmaceutical company’s stock worth $3,038,000 after acquiring an additional 2,805 shares during the last quarter. Hilltop National Bank increased its stake in Pfizer by 8.2% in the 4th quarter. Hilltop National Bank now owns 19,077 shares of the biopharmaceutical company’s stock worth $506,000 after acquiring an additional 1,450 shares during the last quarter. A. D. Beadell Investment Counsel Inc. increased its stake in Pfizer by 7.7% in the 4th quarter. A. D. Beadell Investment Counsel Inc. now owns 47,211 shares of the biopharmaceutical company’s stock worth $1,252,000 after acquiring an additional 3,375 shares during the last quarter. Finally, ST Germain D J Co. Inc. increased its stake in Pfizer by 17.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 30,269 shares of the biopharmaceutical company’s stock worth $803,000 after acquiring an additional 4,515 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Trading Down 0.5 %

NYSE PFE opened at $26.73 on Friday. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a 50 day simple moving average of $26.18 and a two-hundred day simple moving average of $28.04. The stock has a market cap of $151.48 billion, a P/E ratio of 36.12, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.17) EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.43%. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 232.43%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. Bank of America reiterated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup initiated coverage on Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective on the stock. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Sanford C. Bernstein initiated coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.